Clinical efficacy of icotinib in treatment of seventeen non-smokers with advanced lung adenocarcinoma

Objective:To investigate the clinical efficacy of icotinib in treatment of non-smokers with advanced lung adenocarcinoma.Methods:Seventeen non-smokers with stage Ⅳ lung adenocarcinoma were enrolled into the study.The regimen was oral intake of icotinib until the disease progression.The response rate,quality of life,adverse reactions of icotinib and relief of clinical symptom were observed.Results:Symptom relief started at d 4～10,12 cases(70.6%) has improved KPS score,complete respose(CR) rate was 0%,partial response(PR) rate was 52.9%(9 cases),stable disease(SD) rate was 35.3%(6 cases),progressive disease(PD) rate was 11.8%(2 cases).There were 9 cases with first-line therapy,CR 0%,PR 66.7%(6 cases),SD 11.1%(1 cases),PD 22.2%(2 cases).There were 8 cases with second-line therapy,CR 0%,PR 37.5%(3 cases),SD 62.5%(5 cases),PD 0%.The major adverse reactions included low-grade dry skin(23.5%),rash(11.8%) and diarrhea(11.8%).Conclusion:Icotinib was effective for non-smokers with advanced lung adenocarcinoma even in first-line therapy.The adverse reaction of icotinib were slight as well.